Mainstream

Inovio outlines BLA submission timeline for INO-3107 and reports $68.4M cash position while advancing DNA medicine pipeline

Inovio outlines BLA submission timeline for INO-3107 and reports $68.4M cash position while advancing DNA medicine pipeline

Post ContentinoRead More

You might also be interested in reading Elevated Ether Volatility Expectations May Be Unfounded.

May 13, 2025
In Mainstream